(Q38099749)

28 August 2017

0 references

Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies (English)

1 reference

28 August 2017

0 references

1 reference

1 reference

Linjuan Xu

1

1 reference

28 August 2017

Jing Cai

2

1 reference

28 August 2017

Qiang Yang

3

1 reference

28 August 2017

Hui Ding

4

1 reference

28 August 2017

Liying Wu

5

1 reference

28 August 2017

Tao Li

6

1 reference

28 August 2017

Zehua Wang

7

1 reference

28 August 2017

18 April 2013

1 reference

Journal of Cancer Research and Clinical Oncology

28 August 2017

1 reference

28 August 2017

139

1 reference

28 August 2017

8

1 reference

28 August 2017

1257-1277

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-013-1435-z

28 August 2017

0 references

cites work

p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Expression of multidrug resistance-associated markers, their relation to quantitative pathologic tumour characteristics and prognosis in advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Tumor necrosis factor receptor 1 functions as a tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Immunohistochemical markers of cell cycle control applied to ovarian and primary peritoneal surface epithelial neoplasms: p21(WAF1/CIP1) predicts survival and good response to platinin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Tumor promoters--microcystin-LR, nodularin and TNF-α and human cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

p16INK4a expression in cytology of ascites and response to chemotherapy in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Glutathione S-transferase expression in benign and malignant ovarian tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Evaluation of the quality of prognosis studies in systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Expression and prognostic significance of Bcl-2 in ovarian tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Limited prognostic value of tissue protein expression levels of BCl-2 in Danish ovarian cancer patients: from the Danish 'MALOVA' ovarian cancer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Glutathione S-transferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Association between glutathione-S-transferase GSTP1 genotypes, GSTP1 over-expression, and outcome in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Overexpression of p21, cyclin E and decreased expression of p27 in DMBA (7, 12‐dimethylbenzanthracene)‐induced rat ovarian carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Immunohistochemical analysis of glutathione S-transferase mu expression in ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Increased expression of multidrug resistance related proteins Pgp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p27KIP1, cyclin E, and cyclin D2, in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Glutathione S-transferase activity and isoenzyme distribution in ovarian tumour biopsies taken before or after cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

The role of glutathione-S-transferase polymorphisms in ovarian cancer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori-related gastric carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Drug resistance in ovarian cancer - the role of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Multidrug resistance in ovarian cancer: comparing an immunocytochemical study and ATP-tumor chemosensitivity assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Prognostic significance of ras/p21 alterations in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

P53, bcl-2, and bax: their relationship and effect on prognosis in early stage epithelial ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Nuclear localisation of glutathione S-transferase pi is an evaluation factor for drug resistance in gynaecological cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Addressing Reporting Biases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

The combined evaluation ofp53 accumulation and of Ki-67 (MIBI) labelling index provides independent information on overall survival of ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Glutathione-S-transferase activity and isoenzyme levels measured by two methods in ovarian cancer, and their value as markers of disease outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherap

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1435-Z

Prognostic factors of ovarian cancer

21 January 2018

1 reference

12 December 2020

Prognostic value of P-glycoprotein and proliferative index in advanced low grade serous ovarian carcinomas.

1 reference

12 December 2020

Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis

1 reference

12 December 2020

p21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma

1 reference

12 December 2020

Expression of ras oncogene p21 protein in normal and neoplastic ovarian tissues: correlation with histopathologic features and receptors for estrogen, progesterone, and epidermal growth factor

1 reference

12 December 2020

Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients.

1 reference

12 December 2020

[Association of EGFR expression with angiogenesis and chemoresistance in ovarian carcinoma].

1 reference

12 December 2020

HER-2/neu and bcl-2 in ovarian carcinoma: clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival

1 reference

12 December 2020

Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival

1 reference

12 December 2020

Immunohistochemical expression of glutathione S-transferase pi (GST-pi) and chemotherapy response in malignant ovarian tumors

1 reference

12 December 2020

Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer.

1 reference

12 December 2020

Factors associated with cytoreducibility among women with ovarian carcinoma

1 reference

12 December 2020

Correlation of MDR-1, nm23-H1 and H Sema E gene expression with histopathological findings and clinical outcome in ovarian and breast cancer patients.

1 reference

12 December 2020

Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma.

1 reference

12 December 2020

[Prognostic factors of ovarian cancer]

1 reference

12 December 2020

Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer

1 reference

12 December 2020

Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6, (IL-6), interleukin-1 beta (IL-1 beta), interleukin-11 (IL-11) and tumour necrosis factor-alpha (TNF-alpha) in p53-characterised human ovarian carcinomas

1 reference

12 December 2020

Glutathione S-transferase activity in epithelial ovarian cancer: Association with response to chemotherapy and disease outcome

1 reference

12 December 2020

The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma

1 reference

12 December 2020

DNA demethylase expression correlates with lung resistance protein expression in common epithelial ovarian cancers

1 reference

12 December 2020

The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma.

1 reference

12 December 2020

Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy

1 reference

12 December 2020

Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression

1 reference

12 December 2020

Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft

1 reference

12 December 2020

Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?

1 reference

12 December 2020

Value of glutathion-S transferase pi as a prognostic factor in epithelial ovarian carcinoma.

1 reference

12 December 2020

EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients

1 reference

12 December 2020

Role of tumour markers, cytogenetics

1 reference

12 December 2020

The prognostic and predictive value of ERCC-1, p53, bcl-2 and bax in epithelial ovarian cancer

1 reference

12 December 2020

Markers of chemoresistance in ovarian carcinomas: an immunohistochemical study of 86 cases

1 reference

12 December 2020

Multidrug resistance-associated biomarkers PGP, GST-pi, Topo-II and LRP as prognostic factors in primary ovarian carcinoma

1 reference

12 December 2020

p21 expression predicts outcome in p53-null ovarian carcinoma

1 reference

12 December 2020

The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.

1 reference

12 December 2020

Prognostic significance of cell cycle proteins and genomic instability in borderline, early and advanced stage ovarian carcinomas

1 reference

12 December 2020

Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer.

1 reference

12 December 2020

Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms

1 reference

12 December 2020

Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma

1 reference

12 December 2020

Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure

1 reference

12 December 2020

Overexpression of p53, EGFR, c-erbB2 and c-erbB3 in endometrioid carcinoma of the ovary

1 reference

12 December 2020

Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study

1 reference

12 December 2020

Decreased expression of p16 in ovarian cancers represents an unfavourable prognostic factor

1 reference

12 December 2020

Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer

1 reference

12 December 2020

Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma

1 reference

12 December 2020

Expression of MDR1 in epithelial ovarian cancer and its association with disease progression

1 reference

12 December 2020

Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers

1 reference

12 December 2020

Inverse expression of Cdk4 and p16 in epithelial ovarian tumors

1 reference

12 December 2020

P-glycoprotein as a prognostic indicator in pre- and postchemotherapy ovarian adenocarcinoma.

1 reference

12 December 2020

Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: A multivariate analysis of expression of p53, retinoblastoma, and related proteins

1 reference

12 December 2020

Long-term prognostic factors for chemotherapy of ovarian cancer

1 reference

12 December 2020

Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer

1 reference

12 December 2020

The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer

1 reference

12 December 2020

Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer

1 reference

12 December 2020

The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy

1 reference

12 December 2020

Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer

1 reference

12 December 2020

Statistical aspects of the analysis of data from retrospective studies of disease

1 reference

12 December 2020

Glutathione S-transferase-pi expression and glutathione concentration in ovarian carcinoma before and after chemotherapy

1 reference

12 December 2020

Bcl-2: bax and bcl-2: Bcl-x ratios by image cytometric quantitation of immunohistochemical expression in ovarian carcinoma: correlation with prognosis

1 reference

12 December 2020

p21WAF1/CIP1 protein expression in primary ovarian cancer

1 reference

12 December 2020

Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant

1 reference

12 December 2020

The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer

1 reference

12 December 2020

E-Cadherin complex protein expression and survival in ovarian carcinoma

1 reference

12 December 2020

Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer

1 reference

12 December 2020

Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer

1 reference

12 December 2020

Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression

1 reference

12 December 2020

MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors

1 reference

12 December 2020

The glutathione S-transferase M1 genotype in ovarian cancer.

1 reference

12 December 2020

Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer

1 reference

12 December 2020

Alteration of p16 and p15 genes in common epithelial ovarian tumors

1 reference

12 December 2020

P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer

1 reference

12 December 2020

Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas

1 reference

12 December 2020

Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma

1 reference

12 December 2020

Analysis of p53, p16(INK4a), pRb and Cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas.

1 reference

12 December 2020

Evaluation of the cyclin-dependent kinase inhibitor p21Cip1 in epithelial ovarian tumors of low malignant potential and adenocarcinomas

1 reference

12 December 2020

Co-expression of the MDR1 gene and HSP27 in human ovarian cancer

1 reference

12 December 2020

10.1007/S00432-013-1435-Z

Identifiers

DOI

1 reference

28 August 2017

1 reference